Medications Associated with Increased Risk of Keratinocyte Carcinoma

Crow, Lauren; Kaizer-Salk, Katherine A.; Juszczak, Hailey M; Arron, Sarah T.

doi:10.1016/j.det.2019.02.005

Cited by 5 publications

(7 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-cancer treatments can often induce a range of adverse effects, and among these, skin cancers have been the subject of considerable scrutiny in both traditional and novel therapeutic approaches [ 1 , 2 , 3 , 4 , 5 ]. It is crucial to determine whether a particular therapy heightens the risk of skin cancer to implement appropriate screening measures before and during treatment.…”

Section: Introductionmentioning

confidence: 99%

Skin Malignancies Due to Anti-Cancer Therapies

Starace,

Rapparini,

Cedirian

2024

Cancers

View full text Add to dashboard Cite

Skin cancers involve a significant concern in cancer therapy due to their association with various treatment modalities. This comprehensive review explores the increased risk of skin cancers linked to different anti-cancer treatments, including classic immunosuppressants such as methotrexate (MTX), chemotherapeutic agents such as fludarabine and hydroxyurea (HU), targeted therapies like ibrutinib and Janus Kinase inhibitors (JAKi), mitogen-activated protein kinase pathway (MAPKP) inhibitors, sonic hedgehog pathway (SHHP) inhibitors, and radiotherapy. MTX, a widely used immunosuppressant in different fields, is associated with basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and cutaneous melanoma (CM), particularly at higher dosages. Fludarabine, HU, and other chemotherapeutic agents increase the risk of non-melanoma skin cancers (NMSCs), including cSCC and BCC. Targeted therapies like ibrutinib and JAKi have been linked to an elevated incidence of NMSCs and CM. MAPKP inhibitors, particularly BRAF inhibitors like vemurafenib, are associated with the development of cSCCs and second primary melanomas (SPMs). SHHP inhibitors like vismodegib have been linked to the emergence of cSCCs following treatment for BCC. Additionally, radiotherapy carries carcinogenic risks, especially for BCCs, with increased risks, especially with younger age at the moment of exposure. Understanding these risks and implementing appropriate screening is crucial for effectively managing patients undergoing anti-cancer therapies.

show abstract

Section: Introductionmentioning

confidence: 99%

Skin Malignancies Due to Anti-Cancer Therapies

Starace,

Rapparini,

Cedirian

2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Photosensitivity is a general term that describes either the common phototoxic response or the much less frequent photoallergic reaction 13‐15 . Drug‐induced photosensitivity refers to the development of a cutaneous disease due to exposure to a chemical agent and sunlight 12,14 .…”

Section: Introductionmentioning

confidence: 99%

“…Some drugs are not only responsible for photosensitivity, but also an increased risk of cutaneous malignancies, such as melanoma and non‐melanoma skin cancer 14 . A number of medications for short‐term and long‐term use have been linked to an increased risk for cSCC such as calcineurin inhibitors, purine synthesis inhibitors, tumor necrosis factor‐alpha inhibitors, antimicrobials (voriconazol; cumulative exposure, through photosensitization/phototoxicity), targeted molecular inhibitors, as well as antihypertensives 2,13,14 …”

Section: Introductionmentioning

confidence: 99%

“…Photosensitivity is a general term that describes either the common phototoxic response or the much less frequent photoallergic reaction. [13][14][15] Drug-induced photosensitivity refers to the development of a cutaneous disease due to exposure to a chemical agent and sunlight. 12,14 UVA radiation (320-400 nm) is the main responsible light type for drug-induced eruptions, due to its deep penetration through the skin.…”

Section: Introductionmentioning

confidence: 99%

“…14 A number of medications for short-term and long-term use have been linked to an increased risk for cSCC such as calcineurin inhibitors, purine synthesis inhibitors, tumor necrosis factor-alpha inhibitors, antimicrobials (voriconazol; cumulative exposure, through photosensitization/phototoxicity), targeted molecular inhibitors, as well as antihypertensives. 2,13,14 Several antihypertensive drugs are photosensitizing and may thus act as cocarcinogens with UVR to increase the risk of skin cancer. [16][17][18][19] The antihypertensive agents reported to cause photosensitive reactions are involved the subtypes of diuretics, angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), calcium channel blockers (CCB) and β-blockers.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of relationship between antihypertensive drug usage and dermatoscopic features in patients with keratinizing skin cancer

Demirdağ

Tuğrul

2021

Dermatologic Therapy

View full text Add to dashboard Cite

Keratinizing skin cancers including actinic keratoses (AK), in situ squamous cell carcinoma/Bowen's disease/intraepidermal carcinoma (IEC), invasive cutaneous squamous cell carcinoma (cSCC) and keratoacanthoma share similar dermatoscopic features and also reveal different patterns that assist in their diagnosis. Recently epidemiological studies reveal the association between antihypertensive drugs and skin cancer risk, especially cSCC. This study aims to determine the dermatoscopic features of keratinizing skin cancer in patients using antihypertensive drug and compare with non-users. A total of 46 patients with 64 keratinizing skin cancer lesions were included in the study. The demographic, clinical characteristic of patients, the number, duration, localization and dermatoscopic features from each lesion were collected. First, we evaluated the dermatoscopic features according to the histopathologic diagnosis. Then, all patients were divided into two groups as users of antihypertensive drugs and non-users. The dermatoscopic features were compared in terms of antihypertensive drug usage and histopathologic diagnosis in antihypertensive drug users and non-users, separately. The users of antihypertensive drugs were 22 (47,8%) and non-users 24 (52,2%). Of the total 64 lesions including 47 AK, 5 IEC, 10 cSCC, and 2 keratoacanthoma were evaluated. White structureless area was found statistically significant in cSCC lesions of patients using antihypertensive drugs (P = .004). This finding in cSCC may be a clue for antihypertensive drug usage and these drugs may be a predisposan factor for dermal fibrosis. Regardless of histopathology, dermatoscopic features show no statistically difference between antihypertensive drug users and non-users (P > .05).Clearer results can be obtained by conducting more detailed and long-term studies.

show abstract

Cutaneous Photosensitivity Diseases

Ibbotson

2024

Rook's Textbook of Dermatology

View full text Add to dashboard Cite

The photodermatoses are a diverse group of conditions in which abnormal responses to light exposure are the hallmark. Photodiagnostic investigations through a specialist unit may be essential to ensure accurate diagnosis and management, and this chapter explores the nature of the photodermatoses and the photodiagnostic techniques that can be applied. Management approaches include early diagnosis, prevention and disease suppression, and awareness of the significant adverse impact on well‐being and psychological health that can occur with photosensitivity. Photoprotection is a mainstay approach for the photodermatoses but is often not sufficient alone for disease control. Desensitisation through natural hardening or light‐based therapies may be feasible, although systemic immunosuppressants and immunomodulators may be required. Awareness of the possibility of vitamin D deficiency is also necessary. This chapter will cover these approaches in detail.

show abstract

Medications Associated with Increased Risk of Keratinocyte Carcinoma

Cited by 5 publications

References 98 publications

Skin Malignancies Due to Anti-Cancer Therapies

Skin Malignancies Due to Anti-Cancer Therapies

Evaluation of relationship between antihypertensive drug usage and dermatoscopic features in patients with keratinizing skin cancer

Cutaneous Photosensitivity Diseases

Contact Info

Product

Resources

About